Fusion Pharmaceuticals Inc. (FUSN) – PRNewswire
-
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
-
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
-
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
-
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
-
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
-
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
-
Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals to Present at Upcoming Investor Conferences
-
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
-
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
-
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R
-
Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals to Present at the Jefferies Healthcare Conference
-
Fusion Pharmaceuticals Announces First Quarter 2023 Financial Results and Clinical Program Updates
-
Fusion Pharmaceuticals to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
-
Fusion Pharmaceuticals Announces Opening of Radiopharmaceutical Manufacturing Facility to Produce Targeted Alpha Therapies for Cancer
-
Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
-
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2059 and Leading Targeted Alpha Therapy Platform at AACR Annual Meeting
-
Fusion Pharmaceuticals Announces IND Clearance for FPI-2068, a Jointly Developed Novel Targeted Alpha Therapy
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1
-
Fusion Pharmaceuticals Announces Fourth Quarter 2022 Financial Results and Clinical Program Updates
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals to Present at the 43rd Annual Cowen Healthcare Conference
-
Fusion Pharmaceuticals to Acquire Phase 2 Program for 225Ac-PSMA I&T, a Radiopharmaceutical Targeting Metastatic Castrate Resistant Prostate Cancer
-
Fusion Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Reports Progress and Provides Recent Corporate Highlights
-
Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Announces Third Quarter 2022 Financial Results and Clinical Program Updates
-
Fusion Pharmaceuticals Appoints Dmitri Bobilev, M.D. as Chief Medical Officer
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fusion Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
-
Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1/2 Study of FPI-1966 In Patients with Advanced Solid Tumors Expressing FGFR3
Back to FUSN Stock Lookup
